MX2022011800A - Metodos para tratar mieloma multiple. - Google Patents
Metodos para tratar mieloma multiple.Info
- Publication number
- MX2022011800A MX2022011800A MX2022011800A MX2022011800A MX2022011800A MX 2022011800 A MX2022011800 A MX 2022011800A MX 2022011800 A MX2022011800 A MX 2022011800A MX 2022011800 A MX2022011800 A MX 2022011800A MX 2022011800 A MX2022011800 A MX 2022011800A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- multiple myeloma
- treating multiple
- antibody
- antigen
- Prior art date
Links
- 206010035226 Plasma cell myeloma Diseases 0.000 title abstract 3
- 208000034578 Multiple myelomas Diseases 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 229940125373 Gamma-Secretase Inhibitor Drugs 0.000 abstract 2
- 239000000427 antigen Substances 0.000 abstract 2
- 102000036639 antigens Human genes 0.000 abstract 2
- 108091007433 antigens Proteins 0.000 abstract 2
- 239000003540 gamma secretase inhibitor Substances 0.000 abstract 2
- BGFTWECWAICPDG-UHFFFAOYSA-N 2-[bis(4-chlorophenyl)methyl]-4-n-[3-[bis(4-chlorophenyl)methyl]-4-(dimethylamino)phenyl]-1-n,1-n-dimethylbenzene-1,4-diamine Chemical compound C1=C(C(C=2C=CC(Cl)=CC=2)C=2C=CC(Cl)=CC=2)C(N(C)C)=CC=C1NC(C=1)=CC=C(N(C)C)C=1C(C=1C=CC(Cl)=CC=1)C1=CC=C(Cl)C=C1 BGFTWECWAICPDG-UHFFFAOYSA-N 0.000 abstract 1
- 102000006942 B-Cell Maturation Antigen Human genes 0.000 abstract 1
- 108010008014 B-Cell Maturation Antigen Proteins 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 238000002648 combination therapy Methods 0.000 abstract 1
- 229960002204 daratumumab Drugs 0.000 abstract 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 abstract 1
- 229960003957 dexamethasone Drugs 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 230000002519 immonomodulatory effect Effects 0.000 abstract 1
- 238000013508 migration Methods 0.000 abstract 1
- 230000005012 migration Effects 0.000 abstract 1
- 201000000050 myeloid neoplasm Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
Abstract
En este documento se proporcionan métodos para tratar el mieloma múltiple (MM) usando dosis específicas de un anticuerpo anti-antígeno de migración de células B (BCMA), varios regímenes de dosificación y, opcionalmente, una terapia combinada con dexametasona, un agente inmunomodulador (por ejemplo, pomalinamida), un anticuerpo anti-CD38 o fragmento de unión a antígeno del mismo (por ejemplo, daratumumab), y un inhibidor de gamma secretasa (GSI), y/o varias combinaciones de los mismos.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202063000229P | 2020-03-26 | 2020-03-26 | |
PCT/US2021/024127 WO2021195362A1 (en) | 2020-03-26 | 2021-03-25 | Methods of treating multiple myeloma |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2022011800A true MX2022011800A (es) | 2023-01-19 |
Family
ID=75540019
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2022011800A MX2022011800A (es) | 2020-03-26 | 2021-03-25 | Metodos para tratar mieloma multiple. |
Country Status (12)
Country | Link |
---|---|
US (1) | US20230118517A1 (es) |
EP (1) | EP4126952A1 (es) |
JP (1) | JP2023520771A (es) |
KR (1) | KR20230005163A (es) |
CN (1) | CN115698069A (es) |
AU (1) | AU2021244215A1 (es) |
BR (1) | BR112022018987A2 (es) |
CA (1) | CA3176257A1 (es) |
IL (1) | IL296723A (es) |
MX (1) | MX2022011800A (es) |
TW (1) | TW202202170A (es) |
WO (1) | WO2021195362A1 (es) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108778329B (zh) | 2016-02-17 | 2022-09-16 | 西雅图基因公司 | Bcma抗体和其用以治疗癌症和免疫病症的用途 |
WO2023081830A2 (en) * | 2021-11-05 | 2023-05-11 | Springworks Therapeutics, Inc. | Compositions and treatments with nirogacestat |
WO2023150627A1 (en) * | 2022-02-03 | 2023-08-10 | Predicine, Inc. | Systems and methods for monitoring of cancer using minimal residual disease analysis |
Family Cites Families (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US662510A (en) | 1899-05-20 | 1900-11-27 | Western Electric Co | Incandescent-lamp socket. |
CH646696A5 (de) | 1980-11-28 | 1984-12-14 | Sandoz Ag | Dibenzazepine, ihre herstellung und verwendung. |
US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
EP0307434B2 (en) | 1987-03-18 | 1998-07-29 | Scotgen Biopharmaceuticals, Inc. | Altered antibodies |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
ES2206447T3 (es) | 1991-06-14 | 2004-05-16 | Genentech, Inc. | Anticuerpo humanizado para heregulina. |
US5834597A (en) | 1996-05-20 | 1998-11-10 | Protein Design Labs, Inc. | Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same |
CN100405399C (zh) | 1999-02-05 | 2008-07-23 | 三星电子株式会社 | 图像纹理恢复方法及其装置 |
US7829693B2 (en) | 1999-11-24 | 2010-11-09 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of a target gene |
JP2003520266A (ja) | 2000-01-24 | 2003-07-02 | メルク シャープ エンド ドーム リミテッド | γ−セクレターゼ阻害薬 |
GB0005251D0 (en) | 2000-03-03 | 2000-04-26 | Merck Sharp & Dohme | Therapeutic compounds |
GB0008710D0 (en) | 2000-04-07 | 2000-05-31 | Merck Sharp & Dohme | Therapeutic compounds |
CA2427206C (en) | 2000-11-02 | 2011-06-28 | Merck Sharp & Dohme Limited | Sulfamides as gamma-secretase inhibitors |
US7468365B2 (en) | 2000-11-17 | 2008-12-23 | Eli Lilly And Company | Lactam compound |
UA77165C2 (en) | 2000-11-17 | 2006-11-15 | Lilly Co Eli | (n)-((s)-2-hydroxy-3-methyl-butyryl)-1-(l-alaninyl)-(s)-1-amino-3-methyl-4,5,6,7-tetrahydro-2h-3-benzazepin-2-one dihydrate, processes for manufacturing and pharmaceutical composition |
WO2004006955A1 (en) | 2001-07-12 | 2004-01-22 | Jefferson Foote | Super humanized antibodies |
GB0223038D0 (en) | 2002-10-04 | 2002-11-13 | Merck Sharp & Dohme | Therapeutic compounds |
GB0223039D0 (en) | 2002-10-04 | 2002-11-13 | Merck Sharp & Dohme | Therapeutic compounds |
GB0225474D0 (en) | 2002-11-01 | 2002-12-11 | Merck Sharp & Dohme | Therapeutic agents |
BRPI0410348A (pt) | 2003-05-14 | 2006-05-30 | Torreypines Therapeutics Inc | compostos e usos dos mesmos na modulação de amilóide-beta |
GB0326039D0 (en) | 2003-11-07 | 2003-12-10 | Merck Sharp & Dohme | Therapeutic agents |
EA016357B1 (ru) | 2004-07-30 | 2012-04-30 | Ринат Ньюросайенс Корп. | Антитела, направленные против бета-амилоидного пептида, и способы их применения |
US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
US8455622B2 (en) | 2006-12-01 | 2013-06-04 | Seattle Genetics, Inc. | Variant target binding agents and uses thereof |
WO2009035522A1 (en) | 2007-09-14 | 2009-03-19 | Albert Einstein College Of Medicine Of Yeshiva University | Use of gamma secretase inhibitors and notch pathway inhibitors for treatment and prevention of renal disease |
ES2458541T3 (es) | 2008-05-02 | 2014-05-06 | Seattle Genetics, Inc. | Métodos y composiciones para elaborar anticuerpos y derivados de anticuerpos con fucosilación del núcleo reducida |
RU2011104348A (ru) | 2008-07-08 | 2012-08-20 | Эбботт Лэборетриз (Us) | Иммуноглобулины с двойным вариабельным доменом против простагландина е2 и их применение |
KR20120060877A (ko) | 2009-09-01 | 2012-06-12 | 아보트 러보러터리즈 | 이원 가변 도메인 면역글로불린 및 이의 용도 |
AU2010306677B2 (en) | 2009-10-15 | 2013-05-23 | Abbvie Inc. | Dual variable domain immunoglobulins and uses thereof |
UY32979A (es) | 2009-10-28 | 2011-02-28 | Abbott Lab | Inmunoglobulinas con dominio variable dual y usos de las mismas |
KR20130100118A (ko) | 2010-08-03 | 2013-09-09 | 아비에 인코포레이티드 | 이원 가변 도메인 면역글로불린 및 이의 용도 |
JOP20210044A1 (ar) | 2010-12-30 | 2017-06-16 | Takeda Pharmaceuticals Co | الأجسام المضادة لـ cd38 |
US10149855B2 (en) | 2014-02-05 | 2018-12-11 | The Trustees Of Columbia University In The City Of New York | Gamma-secretase inhibition reduce APOC3 levels and plasma triglycerides |
EP3166627A1 (en) | 2014-07-11 | 2017-05-17 | Genentech, Inc. | Notch pathway inhibition |
TWI800341B (zh) | 2015-11-03 | 2023-04-21 | 美商健生生物科技公司 | 抗cd38抗體之皮下調配物及其用途 |
CN108778329B (zh) | 2016-02-17 | 2022-09-16 | 西雅图基因公司 | Bcma抗体和其用以治疗癌症和免疫病症的用途 |
US10307388B2 (en) | 2016-12-29 | 2019-06-04 | The United States Of America As Represented By The Secretary Of The Navy | Compositions and methods for diagnosis and treatment of inflammation |
WO2018201051A1 (en) | 2017-04-28 | 2018-11-01 | Novartis Ag | Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor |
WO2019094626A1 (en) | 2017-11-08 | 2019-05-16 | Fred Hutchinson Cancer Research Center | Bispecific antibody compositions and related methods for improved pretargeted radioimunotherapies |
BR112020023975A2 (pt) | 2018-05-24 | 2021-02-23 | Ayala Pharmaceuticals Inc. | composições que compreendem os compostos de bisfluoroalquil-1,4-benzodiazepinona e imunoterapêuticos e métodos de uso das mesmas |
AU2019277029C1 (en) | 2018-06-01 | 2024-01-04 | Novartis Ag | Binding molecules against BCMA and uses thereof |
US11773369B2 (en) | 2018-08-03 | 2023-10-03 | The Regents Of The University Of California | Generation of human spinal cord neural stem cells |
EP3873608A1 (en) | 2018-10-31 | 2021-09-08 | Gilead Sciences, Inc. | Substituted 6-azabenzimidazole compounds having hpk1 inhibitory activity |
WO2020212914A1 (en) | 2019-04-19 | 2020-10-22 | Janssen Biotech, Inc. | Combination therapies comprising daratumumab, bortezomib, thalidomide and dexamethasone and their uses |
US10590087B1 (en) | 2019-08-09 | 2020-03-17 | Pfizer Inc. | Solid state forms of (S)-2-(((S)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl)amino)-N-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1H-imidazol-4-yl)pentanamide and uses thereof |
-
2021
- 2021-03-25 BR BR112022018987A patent/BR112022018987A2/pt unknown
- 2021-03-25 MX MX2022011800A patent/MX2022011800A/es unknown
- 2021-03-25 WO PCT/US2021/024127 patent/WO2021195362A1/en unknown
- 2021-03-25 KR KR1020227036505A patent/KR20230005163A/ko unknown
- 2021-03-25 CA CA3176257A patent/CA3176257A1/en active Pending
- 2021-03-25 JP JP2022558137A patent/JP2023520771A/ja active Pending
- 2021-03-25 US US17/913,542 patent/US20230118517A1/en active Pending
- 2021-03-25 IL IL296723A patent/IL296723A/en unknown
- 2021-03-25 CN CN202180038796.8A patent/CN115698069A/zh active Pending
- 2021-03-25 AU AU2021244215A patent/AU2021244215A1/en active Pending
- 2021-03-25 EP EP21719439.8A patent/EP4126952A1/en active Pending
- 2021-03-26 TW TW110111220A patent/TW202202170A/zh unknown
Also Published As
Publication number | Publication date |
---|---|
US20230118517A1 (en) | 2023-04-20 |
JP2023520771A (ja) | 2023-05-19 |
KR20230005163A (ko) | 2023-01-09 |
CN115698069A (zh) | 2023-02-03 |
TW202202170A (zh) | 2022-01-16 |
EP4126952A1 (en) | 2023-02-08 |
CA3176257A1 (en) | 2021-09-30 |
BR112022018987A2 (pt) | 2022-11-01 |
WO2021195362A1 (en) | 2021-09-30 |
AU2021244215A1 (en) | 2022-10-13 |
IL296723A (en) | 2022-11-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2022011800A (es) | Metodos para tratar mieloma multiple. | |
CL2020000263A1 (es) | Conjugado de anticuerpo monoclonal contra bcma-fármaco. | |
MX2017015811A (es) | Tratamiento de cancer por bloqueo combinado de las trayectorias de señalizacion de muerte programada 1 (pd)-1 y receptor 4 de quimiocina c-x-c(cxcr4). | |
MX2021012407A (es) | Terapia de combinacion con un anticuerpo anti bcma y un inhibidor de gamma secretasa. | |
EA202191176A1 (ru) | Поливалентные модуляторы регуляторных т-клеток | |
EA201692285A8 (ru) | Ингибиторы ezh2 для лечения лимфомы | |
MX2020008445A (es) | Metodos para tratar el cancer con anticuerpos anti-pd-1. | |
MX2018002554A (es) | Combinaciones de inhibidores de btk para tratar mieloma multiple. | |
EA201891388A1 (ru) | Ингибиторы калликреина плазмы и их применение для лечения обострения наследственного ангионевротического отека | |
JOP20210166A1 (ar) | علاج الصداع الناتج عن فرط استعمال الأدوية باستخدام أجسام مضادة لـcgrp أو أجسام مضادة لـcgrp-r | |
MX2021004351A (es) | Metodo para el tratamiento de miastenia grave. | |
EA202191170A1 (ru) | Комбинированная терапия для лечения гематологических заболеваний | |
JOP20220168A1 (ar) | طرق علاج الطحال | |
ZA202200906B (en) | Anti-her2/anti-4-1bb bispecific antibody and use thereof | |
EP4252847A3 (en) | Regimens and methods of treating multiple sclerosis using ofatumumab | |
ZA202200905B (en) | Anti-egfr/anti-4-1bb bispecific antibody and use thereof | |
ECSP21091482A (es) | Terapia de combinación | |
EA202090565A1 (ru) | Композиции и способы лечения диффузной в-крупноклеточной лимфомы | |
CO2022009433A2 (es) | Uso de isatuximab para el tratamiento del mieloma múltiple recidivante y/o refractario | |
MX2019014330A (es) | Paradigma de tratamiento para un tratamiento de combinacion de anticuerpo anti-cd19 y venetoclax. | |
MX2020005557A (es) | Agonistas de fxr para el tratamiento de enfermedades hepaticas. | |
CO2021014370A2 (es) | Regímenes de dosificación para anticuerpos anti-vrs y composiciones que los incluyen | |
MX2022000441A (es) | Metodos para tratar o prevenir la atrofia muscular espinal. | |
MX2021001604A (es) | Tratamiento del cáncer con un anticuerpo. | |
MX2023002852A (es) | Terapia de combinacion para el cancer. |